

FIG. 1



FIG. 2



FIG. 3


Marker BCL6 (N= 278)
Proportion of disease-free Patients
1.0
0.8
0.6
0.4
0.2
0.0
Score>=Q50
Score<Q50
0
20
40
60
80
100
120
140
Time (months)

FIG. 4


Marker CDK6 (N= 278)
Proportion of disease-free Patients
1.0
0.8
0.6
0.4
0.2
0.0
Score>=Q50
Score<Q50
0
20
40
60
80
100
120
140
Time (months)

FIG. 5


Marker PITX2 (N= 278)
Proportion of disease-free Patients
1.0
0.8
0.6
0.4
0.2
0.0
Score>=Q50
Score<Q50
0
20
40
60
80
100
120
140
Time (months)

FIG. 6


Marker STMN1 (N= 278)
Proportion of disease-free Patients
1.0
0.8
0.6
0.4
0.2
0.0
Score>=Q50
Score<Q50
0
20
40
60
80
100
120
140
Time (months)

FIG. 7


Marker TBC1D3 (N= 278)
Proportion of disease-free Patients
1.0
0.8
0.6
0.4
0.2
0.0
Score>=Q50
Score<Q50
0
20
40
60
80
100
120
140
Time (months)

FIG. 8



FIG. 9


SEQ ID NO: 696
Proportion of disease-free Patients
1.0
0.8
0.6
0.4
0.2
0.0
Meth<=Q50
Meth>Q50
0
20
40
60
80
100
120
140
Time (months)

FIG. 10


SEQ ID NO: 888
Proportion of disease-free Patients
1.0
0.8
0.6
0.4
0.2
0.0
Meth<=Q50
Meth>Q50
0
20
40
60
80
100
120
140
Time (months)

FIG. 11


SEQ ID NO: 1008
Proportion of disease-free Patients
1.0
0.8
0.6
0.4
0.2
0.0
Meth<=Q50
Meth>Q50
0
20
40
60
80
100
120
140
Time (months)

FIG. 12


SEQ ID NO: 794
Proportion of disease-free Patients
1.0
0.8
0.6
0.4
0.2
0.0
Meth<=Q50
Meth>Q50
0
20
40
60
80
100
120
140
Time (months)

FIG. 13


SEQ ID NO: 980
Proportion of disease-free Patients
1.0
0.8
0.6
0.4
0.2
0.0
Meth<=Q50
Meth>Q50
0
20
40
60
80
100
120
140
Time (months)

FIG. 14


SEQ ID NO: 914
Proportion of disease-free Patients
1.0
0.8
0.6
0.4
0.2
0.0
Meth<=Q50
Meth>Q50
0
20
40
60
80
100
120
140
Time (months)

FIG. 15


SEQ ID NO: 806
Proportion of disease-free Patients
1.0
0.8
0.6
0.4
0.2
0.0
Meth<=Q50
Meth>Q50
0
20
40
60
80
100
120
140
Time (months)

FIG. 16


SEQ ID NO: 966
Proportion of disease-free Patients
1.0
0.8
0.6
0.4
0.2
0.0
Meth<=Q50
Meth>Q50
0
20
40
60
80
100
120
140
Time (months)

FIG. 17


SEQ ID NO: 804
Proportion of disease-free Patients
1.0
0.8
0.6
0.4
0.2
0.0
Meth<=Q50
Meth>Q50
0
20
40
60
80
100
120
140
Time (months)

FIG. 18


SEQ ID NO: 1076
Proportion of disease-free Patients
1.0
0.8
0.6
0.4
0.2
0.0
Meth<=Q50
Meth>Q50
0
20
40
60
80
100
120
140
Time (months)

FIG. 19


SEQ ID NO: 618
Proportion of disease-free Patients
1.0
0.8
0.6
0.4
0.2
0.0
Meth<=Q50
Meth>Q50
0
20
40
60
80
100
120
140
Time (months)

FIG. 20


SEQ ID NO: 1054
Proportion of disease-free Patients
1.0
0.8
0.6
0.4
0.2
0.0
Meth<=Q50
Meth>Q50
0
20
40
60
80
100
120
140
Time (months)

FIG. 21


SEQ ID NO: 1016
Proportion of disease-free Patients
1.0
0.8
0.6
0.4
0.2
0.0
Meth<=Q50
Meth>Q50
0
20
40
60
80
100
120
140
Time (months)

FIG. 22


SEQ ID NO: 984
Proportion of disease-free Patients
1.0
0.8
0.6
0.4
0.2
0.0
Meth<=Q50
Meth>Q50
0
20
40
60
80
100
120
140
Time (months)

FIG. 23


SEQ ID NO: 916
Proportion of disease-free Patients
1.0
0.8
0.6
0.4
0.2
0.0
Meth<=Q50
Meth>Q50
0
20
40
60
80
100
120
140
Time (months)

FIG. 24


SEQ ID NO: 1082
Proportion of disease-free Patients
1.0
0.8
0.6
0.4
0.2
0.0
Meth<=Q50
Meth>Q50
0
20
40
60
80
100
120
140
Time (months)

FIG. 25


SEQ ID NO: 974
Proportion of disease-free Patients
1.0
0.8
0.6
0.4
0.2
0.0
Meth<=Q50
Meth>Q50
0
20
40
60
80
100
120
140
Time (months)

FIG. 26


SEQ ID NO: 970
Proportion of disease-free Patients
1.0
0.8
0.6
0.4
0.2
0.0
Meth<=Q50
Meth>Q50
0
20
40
60
80
100
120
140
Time (months)

FIG. 27


SEQ ID NO: 1056
Proportion of disease-free Patients
1.0
0.8
0.6
0.4
0.2
0.0
Meth<=Q50
Meth>Q50
0
20
40
60
80
100
120
140
Time (months)

FIG. 28


SEQ ID NO: 1048
Proportion of disease-free Patients
1.0
0.8
0.6
0.4
0.2
0.0
Meth<=Q50
Meth>Q50
0
20
40
60
80
100
120
140
Time (months)

FIG. 29



FIG. 30


SEQ ID NO: 1046
Proportion of disease-free Patients
1.0
0.8
0.6
0.4
0.2
0.0
Meth<=Q50
Meth>Q50
0
20
40
60
80
100
120
140
Time (months)

FIG. 31


SEQ ID NO: 975
Proportion of disease-free Patients
1.0
0.8
0.6
0.4
0.2
0.0
Meth<=Q50
Meth>Q50
0
20
40
60
80
100
120
140
Time (months)

FIG. 32


SEQ ID NO: 1036
Proportion of disease-free Patients
1.0
0.8
0.6
0.4
0.2
0.0
Meth<=Q50
Meth>Q50
0
20
40
60
80
100
120
140
Time (months)

FIG. 33


SEQ ID NO: 866
Proportion of disease-free Patients
1.0
0.8
0.6
0.4
0.2
0.0
Meth<=Q50
Meth>Q50
0
20
40
60
80
100
120
140
Time (months)

FIG. 34


Marker ABCA8 (N= 278)
Proportion of disease-free Patients
1.0
0.8
0.6
0.4
0.2
0.0
Score>=Q50
Score<Q50
0
20
40
60
80
100
120
140
Time (months)

FIG. 35


Marker BCL6 (N= 278)
Proportion of disease-free Patients
1.0
0.8
0.6
0.4
0.2
0.0
Score>=Q50
Score<Q50
0
20
40
60
80
100
120
140
Time (months)

FIG. 36


Marker CDK6 (N= 278)
Proportion of disease-free Patients
1.0
0.8
0.6
0.4
0.2
0.0
Score>=Q50
Score<Q50
0
20
40
60
80
100
120
140
Time (months)

FIG. 37


Marker CGB1 (N= 278)
Proportion of disease-free Patients
1.0
0.8
0.6
0.4
0.2
0.0
Score>=Q50
Score<Q50
0
20
40
60
80
100
120
140
Time (months)

FIG. 38


Marker ERBB2 (N= 278)
Proportion of disease-free Patients
1.0
0.8
0.6
0.4
0.2
0.0
Score>=Q50
Score<Q50
0
20
40
60
80
100
120
140
Time (months)

FIG. 39


Marker ONECUT2 (N= 278)
Proportion of disease-free Patients
1.0
0.8
0.6
0.4
0.2
0.0
Score>=Q50
Score<Q50
0
20
40
60
80
100
120
140
Time (months)

FIG. 40


Marker PITX2 (N= 278)
Proportion of disease-free Patients
1.0
0.8
0.6
0.4
0.2
0.0
Score>=Q50
Score<Q50
0
20
40
60
80
100
120
140
Time (months)

FIG. 41


Marker PLAU (N= 278)
Proportion of disease-free Patients
1.0
0.8
0.6
0.4
0.2
0.0
Score>=Q50
Score<Q50
0
20
40
60
80
100
120
140
Time (months)

FIG. 42


Marker STMN1 (N= 278)
Proportion of disease-free Patients
1.0
0.8
0.6
0.4
0.2
0.0
Score>=Q50
Score<Q50
0
20
40
60
80
100
120
140
Time (months)

FIG. 43


Marker TBC1D3 (N= 278)
Proportion of disease-free Patients
1.0
0.8
0.6
0.4
0.2
0.0
Score>=Q50
Score<Q50
0
20
40
60
80
100
120
140
Time (months)

FIG. 44



FIG. 45


P
0.000
0.025
0.050
0.075
0.100
PSA-T
STMN1
S100A2
SFN
PRKCD
SYK
VTN
GRIN2D
TGFBR2
COX7A2L
KLK3
TP73
ESR2
ERBB3
TES
BCAR1
PCAF
CDKN2B
TGFB3
HIC1

FIG. 46

FIG. 47




Responder
Nonresponder
WBP11 WBP11 WBP11 WBP11 285
ESR2 ESR2 ESR2 ESR2 ESR2 148
APC APC APC APC 65
ELK1 ELK1 ELK1 ELK1 302
ERBB2 ERBB2 ERBB2 312
CSPG2 CSPG2 CSPG2 21
TGFBR2 TGFBR2 TGFBR2 TGFBR2 43
HSPB1 HSPB1 HSPB1 HSPB1 113
PSAT1 PSAT1 PSAT1 PSAT1 PSAT1 124
STK11 30
TMEFF2 TMEFF2 74
TFF1 TFF1 TFF1 314
CDK6 CDK6 CDK6 294
S100A2 S100A2 S100A2 42
0.04578 0.04578 0.04578 0.04578
0.04562 0.04562 0.04562 0.04562 0.04562
0.04071 0.04071 0.04071 0.04071
0.03708 0.03708 0.03708 0.03708
0.03492 0.03492 0.03492
0.03145 0.03145 0.03145
0.03107 0.03107 0.03107 0.03107
0.02251 0.02251 0.02251 0.02251
0.01805 0.01805 0.01805 0.01805 0.01805
0.00704
0.00617 0.00617
0.00579 0.00579 0.00579
0.00108 0.00108 0.00108
0.00094 0.00094 0.00094
2
1.6
1.2
0.8
0.4
0
−0.4
−0.8
−1.2
−1.6
−2

FIG. 48


Responder
Nonresponder
APC 0.04389
CYP2D6 0.04417
ORC4L 0.04336
WBP11 0.04133
ORC4L 0.03996
CDK6 0.03876
APC 0.03524
TFF1 0.03438
TP53 0.03409
BCL6 0.03361
CGA 0.03318
(NM_138433) 0.03148
PRKCD 0.03087
ESR2 0.03038
SYK 0.02767
DAG1 0.02754
(Chr.8q12.1) 0.02713
RASSF1 0.02597
ELK1 0.02578
PLAU 0.02293
"Q8WUT3" 0.02054
TMEFF2 0.01902
BCL6 0.01889
PCAF 0.0173
ESR2 0.01724
PCAF 0.01409
BCL6 0.01399
COX7A2L 0.01306
SYK 0.01177
PSAT1 0.01074
ERBB2 0.01021
CG81 0.01006
ESR2 0.00985
S100A2 0.00922
ESR2 0.00834
HSPB1 0.00742
STK11 0.00704
ELK1 0.00691
WBP11 0.00658
CSPG2 0.00409
CGA 0.00392
TGFBR2 0.00161
TMEFF2 0.00157
S100A2 0.00146
HSPB1 0.00139
TFF1 0.00043
CDK6 0.00018
S100A2 1e−04
2
1.6
1.2
0.8
0.4
0
−0.4
−0.8
−1.2
−1.6
−2

FIG. 49



FIG. 50



FIG. 51



FIG. 52


St. Gallen vs. Methylation Marker
Proportion of disease-free Patients
1.0
0.8
0.6
0.4
0.2
0.0
0
20
40
60
80
100
120
140
Time (months)
Score>=Q50 (n=135)
Score<Q50 (n=134)
St Gallen high risk (n=197)
St Gallen low risk (n=72)

FIG. 53



FIG. 54


100%
80%
60%
40%
20%
0%
0
1
2
3
4
5
6
7
8
9
11
13
hypometh., n=400, events=38
hypermeth., n=100, events=15
p=0.089, cut off=1.3% (optimized)

FIG. 55


100%
80%
60%
40%
20%
0%
hypometh., n=400, events=38
hypermeth., n=100, events=15
p=0.089, cut off=1.3% (optimized)
0
1
2
3
4
5
6
7
8
9
11
13

FIG. 56


100%
80%
60%
40%
20%
0%
hypometh., n=316, events=26
hypermeth., n=106, events=18
p=0.037, cut off=50.9% (optimized)
0
1
2
3
4
5
6
7
8
9
11
13

FIG. 57


100%
80%
60%
40%
20%
0%
hypometh., n=329, events=14
hypermeth., n=93, events=13
p=0.0029, cut off=52.9% (optimized)
0
1
2
3
4
5
6
7
8
9
11
13

FIG. 58


100%
80%
60%
40%
20%
0%
hypometh., n=354, events=30
hypermeth., n=106, events=17
p=0.056, cut off=4.8% (optimized)
0
1
2
3
4
5
6
7
8
9
11
13

FIG. 59


100%
80%
60%
40%
20%
0%
hypometh., n=354, events=15
hypermeth., n=106, events=13
p=0.065, cut off=4.8% (optimized)
0
1
2
3
4
5
6
7
8
9
11
13

FIG. 60


100%
80%
60%
40%
20%
0%
hypometh., n=212, events=13
hypermeth., n=304, events=42
p=0.01, cut off=13.1% (optimized)
0
1
2
3
4
5
6
7
8
9
11
13

FIG. 61


100%
80%
60%
40%
20%
0%
hypometh., n=217, events=4
hypermeth., n=299, events=27
p=0.0012, cut off=14.3% (optimized)
0
1
2
3
4
5
6
7
8
9
11
13

FIG. 62


100%
80%
60%
40%
20%
0%
hypometh., n=354, events=34
hypermeth., n=182, events=22
p=0.28, cut off=94.6% (optimized)
0
1
2
3
4
5
6
7
8
9
11
13

FIG. 63


100%
80%
60%
40%
20%
0%
hypometh., n=428, events=21
hypermeth., n=108, events=10
p=0.078, cut off=97% (optimized)
0
1
2
3
4
5
6
7
8
9
11
13

FIG. 64


100%
80%
60%
40%
20%
0%
0
2
4
6
8
10
12
14
hypometh., n=104, events=30
hypermeth., n=310, events=109
p=0.21, cut off=0% (optimized)

FIG. 65


100%
80%
60%
40%
20%
0%
hypometh., n=269, events=47
hypermeth., n=145, events=19
p=0.23, cut off=0.6% (optimized)
0
2
4
6
8
10
12
14

FIG. 66


100%
80%
60%
40%
20%
0%
0
2
4
6
8
10
12
14
hypometh., n=243, events=71
hypermeth., n=169, events=66
p=0.012, cut off=49.6% (optimized)

FIG. 67



FIG. 68


100%
80%
60%
40%
20%
0%
0
2
4
6
8
10
12
14
hypometh., n=305, events=91
hypermeth., n=108, events=47
p=0.011, cut off=3.2% (optimized)

FIG. 69


100%
80%
60%
40%
20%
0%
hypometh., n=322, events=43
hypermeth., n=91, events=22
p=0.0082, cut off=5.5% (optimized)
0
2
4
6
8
10
12
14

FIG. 70


100%
80%
60%
40%
20%
0%
0
2
4
6
8
10
12
14
hypometh., n=280, events=73
hypermeth., n=132, events=64
p=1.4e−06, cut off=35.4% (optimized)

FIG. 71


100%
80%
60%
40%
20%
0%
0
2
4
6
8
10
12
14
hypometh., n=301, events=35
hypermeth., n=111, events=30
p=1.7e−05, cut off=41.2% (optimized)

FIG. 72


100%
80%
60%
40%
20%
0%
0
2
4
6
8
10
12
14
hypometh., n=294, events=83
hypermeth., n=114, events=52
p=0.00026, cut off=56.1% (optimized)

FIG. 73


100%
80%
60%
40%
20%
0%
0
2
4
6
8
10
12
14
hypometh., n=322, events=42
hypermeth., n=86, events=21
p=0.0026, cut off=61.9% (optimized)

FIG. 74


100%
80%
60%
40%
20%
0%
0
2
4
6
8
10
12
14
hypometh., n=172, events=63
hypermeth., n=238, events=72
p=0.26, cut off=0% (optimized)

FIG. 75


100%
80%
60%
40%
20%
0%
hypometh., n=193, events=36
hypermeth., n=217, events=26
p=0.077, cut off=0% (optimized)
0
2
4
6
8
10
12
14

FIG. 76


100%
80%
60%
40%
20%
0%
0
2
4
6
8
10
12
14
hypometh., n=332, events=100
hypermeth., n=83, events=39
p=0.004, cut off=98.6% (optimized)

FIG. 77


100%
80%
60%
40%
20%
0%
0
2
4
6
8
10
12
14
hypometh., n=332, events=42
hypermeth., n=83, events=24
p=0.00022, cut off=98.6% (optimized)

FIG. 78


100%
80%
60%
40%
20%
0%
0
2
4
6
8
10
12
14
hypometh., n=296, events=87
hypermeth., n=115, events=50
p=0.0065, cut off=60.9% (optimized)

FIG. 79


100%
80%
60%
40%
20%
0%
hypometh., n=119, events=23
hypermeth., n=292, events=41
p=0.15, cut off=49.2% (optimized)
0
2
4
6
8
10
12
14

FIG. 80


100%
80%
60%
40%
20%
0%
Score −, n=291, events=23
Score +, n=125, events=21
p=0.023, cut off=0.7% quantile (optimized)
0
1
2
3
4
5
6
7
8
9
11
13

FIG. 81


100%
80%
60%
40%
20%
0%
Score −, n=299, events=11
Score +, n=117, events=16
p=0.00084, cut off=0.72% quantile (optimized)
0
1
2
3
4
5
6
7
8
9
11
13

FIG. 82


100%
80%
60%
40%
20%
0%
Score −, n=299, events=25
Score +, n=117, events=19
p=0.037, cut off=0.72% quantile (optimized)
0
1
2
3
4
5
6
7
8
9
11
13

FIG. 83


100%
80%
60%
40%
20%
0%
Score −, n=166, events=2
Score +, n=250, events=25
p=0.0014, cut off=0.4% quantile (optimized)
0
1
2
3
4
5
6
7
8
9
11
13

FIG. 84


100%
80%
60%
40%
20%
0%
Score −, n=329, events=30
Score +, n=93, events=14
p=0.17, cut off=0.78% quantile (optimized)
0
1
2
3
4
5
6
7
8
9
11
13

FIG. 85


100%
80%
60%
40%
20%
0%
Score −, n=135, events=1
Score +, n=287, events=26
p=0.0048, cut off=0.32% quantile (optimized)
0
1
2
3
4
5
6
7
8
9
11
13

FIG. 86


100%
80%
60%
40%
20%
0%
Score −, n=336, events=29
Score +, n=119, events=17
p=0.1, cut off=0.74% quantile (optimized)
0
1
2
3
4
5
6
7
8
9
11
13

FIG. 87


100%
80%
60%
40%
20%
0%
Score −, n=200, events=5
Score +, n=255, events=23
p=0.0081, cut off=0.44% quantile (optimized)
0
1
2
3
4
5
6
7
8
9
11
13

FIG. 88


100%
80%
60%
40%
20%
0%
0
2
4
6
8
10
12
14
Score −, n=321, events=95
Score +, n=91, events=42
p=0.0015, cut off=0.78% quantile (optimized)

FIG. 89


100%
80%
60%
40%
20%
0%
0
2
4
6
8
10
12
14
Score −, n=329, events=43
Score +, n=83, events=21
p=0.003, cut off=0.8% quantile (optimized)

FIG. 90


100%
80%
60%
40%
20%
0%
Score −, n=263, events=66
Score +, n=148, events=70
p=8.9e−07, cut off=0.64% quantile (optimized)
0
2
4
6
8
10
12
14

FIG. 91


100%
80%
60%
40%
20%
0%
Score −, n=271, events=30
Score +, n=140, events=34
p=5.4e−05, cut off=0.66% quantile (optimized)
0
2
4
6
8
10
12
14

FIG. 92


100%
80%
60%
40%
20%
0%
Score −, n=296, events=79
Score +, n=115, events=57
p=1.9e−06, cut off=0.72% quantile (optimized)
0
2
4
6
8
10
12
14

FIG. 93


100%
80%
60%
40%
20%
0%
Score −, n=312, events=37
Score +, n=99, events=27
p=3.5e−05, cut off=0.76% quantile (optimized)
0
2
4
6
8
10
12
14

FIG. 94


100%
80%
60%
40%
20%
0%
Score −, n=280, events=73
Score +, n=132, events=64
p=1.1e−06, cut off=0.68% quantile (optimized)
0
2
4
6
8
10
12
14

FIG. 95


100%
80%
60%
40%
20%
0%
Score −, n=264, events=28
Score +, n=148, events=37
p=1.5e−05, cut off=0.64% quantile (optimized)
0
2
4
6
8
10
12
14

FIG. 96



FIG. 97



FIG. 98



FIG. 99



FIG. 100



FIG. 101



FIG. 102A



FIG. 102B



FIG. 102C



FIG. 102D



FIG. 103A



FIG. 103B



FIG. 103C



FIG. 103D



FIG. 104A



FIG. 104B



FIG. 104C



FIG. 104D



FIG. 105A



FIG. 105B



FIG. 105C



FIG. 105D

0
20
40
60
80
100
85 (20.14%)
236 (55.92%)
101 (23.93%)
0
20
40
60
80
100
253 (49.03%)
55 (10.66%)
208 (40.31%)

FIG. 106

METNCRKLVSACVQLGVQPAAVECLFSKDSEIKKVEFTDSPESRKEAASSKFFPRQ
HPGANEKDKSQQGKNEDVGAEDPSKKKRQRRQRTHFTSQQLQELEATFQRNRYP
DMSTREEIAVWTNLTEARVRVWFKNRRAKWRKRERNQQAELCKNGFGPQFNGL
MQPYDDMYPGYSYNNWAAKGLTSASLSTKSFPFFNSMNVNPLSSQSMFSPPNSISS
MSMSSSMVPSAVTGVPGSSLNSLNNLNNLSSPSLNSAVPTPACPYAPPTPPYVYRDT
CNSSLASLRLKAKQHSSFGYASVQNPASNLSACQYAVDRPV

FIG. 107

FIG. 108


Amplificate 1
Amplificate 2
100
90
80
70
60
50
40
30
20
10
0
Amplificate 8
Amplificate 9
Amplificate 10
Amplificate 11
Amplificate 3
Amplificate 4
Amplificate 5
Amplificate 6
Amplificate 7

FIG. 109


111.90 Mb
111.90 Mb
111.90 Mb
111.90 Mb
111.91 Mb
111.91 Mb
111.91 Mb
111.91 Mb
111.91 Mb
111.92 Mb
111.92 Mb
111.92
24.54 Kb
AC017068.7.1.201627 >
PITX2
Enembl known trans
PITX2
Enembl known trans
PITX2
Enembl known trans
NP_000316
Enembl known trans

FIG. 110